KOD
Kodiak Sciences Inc.
NASDAQ · Healthcare · Biotechnology · US
$91.00
−1.45%Price chart
Sep 8Sep 11Sep 16Sep 21Sep 24Sep 29Oct 2Oct 7
Key dataOct 7, 2026
Open$91.74
From 52W high−7.58%
Volume818652.00
Market cap$5.72B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 7, 2026
Open
$91.74
From 52W high
−7.58%
Volume
818652.00
Market cap
$5.72B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−25.9x
P/E (TTM)
—
RSI (14)
82.3
MomentumView details →
1D Return
−1.45%
YTD Return
+232.22%
SummaryUpdated Jun 1, 2026
Kodiak Sciences Inc. (NASDAQ:KOD) is a clinical-stage biopharmaceutical company founded in 2009 and based in Palo Alto, California. Originally incorporated as Oligasis, LLC, the company changed its name to Kodiak Sciences in September 2015 and went public in October 2018. Kodiak focuses on developing novel therapeutics to treat retinal diseases, with its lead drug candidate currently in late-stage clinical trials for several sight-threatening conditions affecting millions of patients worldwide.
Similar companies
Latest newsMore news →
Kodiak Sciences Inc. announced that it will present clinical data from all three late-stage programs at AAO 2026, including Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted, Phase 3 GLOW2 data for Zenkuda, and Phase 1b APEX data for KSI-101.8h agoRegeneron Pharmaceuticals stock traded lower on Monday, likely in reaction to positive Phase 3 DAYBREAK trial data from Kodiak Sciences for wet age-related macular degeneration.9d agoKodiak Sciences announced that its eye disease drug met its clinical trial goals, sending the company's shares up 123%.9d ago